文献速递临床试验与 GCP流行病学与生物统计

老年卵巢癌治疗中的老年筛查:GERSOC实用整群随机对照试验研究方案

GERiatric Screening in the treatment of elderly patients with Ovarian Carcinoma (GERSOC): study protocol for a pragmatic, cluster randomised controlled trial.
PubMed 文献 · Trials · 2020-02-22

GERSOC试验是在荷兰至少20家医院开展的实用整群随机对照试验,计划纳入320例≥70岁原发性晚期卵巢癌患者。医院随机分为老年筛查组(G8问卷和Timed Up and Go测试)或常规照护组,主要结局为两组完成标准与调整治疗百分比差异。

要点

  • 老年筛查组 unfit 患者转诊老年科评估治疗建议
  • 主要结局为两组完成标准与调整治疗百分比差异
  • 次要结局包括生活质量、成本效果和生存

核心结论

  • 该试验旨在为老年筛查用于老年晚期卵巢癌治疗决策提供证据。
  • 若证实可行、有益且成本效果良好,老年筛查可能纳入常规临床实践。

研究设计与样本

  • 实用整群随机对照试验,在荷兰至少20家医院开展。
  • 计划纳入320例≥70岁原发性晚期卵巢癌患者。
  • 医院随机分配至老年筛查照护组或常规照护组。

关键数值与推荐

  • 老年筛查由G8问卷和Timed Up and Go测试组成。
  • 筛查判定为fit的患者接受标准治疗。
  • 筛查判定为unfit的患者转诊老年科医生进行分析和治疗建议。
  • 主要结局为两组完成标准与调整治疗百分比差异。
  • 次要结局包括生活质量、成本效果和生存。

临床怎么用

  • 对≥70岁晚期卵巢癌患者,可用G8问卷和Timed Up and Go测试进行老年筛查。
  • 筛查unfit者转诊老年科医生获取分析和治疗建议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 40% of the newly diagnosed patients with advanced ovarian cancer are aged 70 years or older. Standard treatment for advanced disease consists of cytoreductive surgery and combination chemotherapy. In older patients, standard treatment is often withheld or prematurely stopped due to suspected frailty. It remains challenging to distinguish fit elderly patients who can endure standard therapy from frail patients who may benefit from an adapted treatment strategy. As a comprehensive geriatric assessment (CGA) can contribute to the identification of frail patients and improve tailored therapy in this population, screening tests were developed to select those who may benefit from a CGA. However, the use of these geriatric screening tests has rarely been compared with usual clinical care. The GERSOC-trial will evaluate whether geriatric screening in elderly patients with advanced-stage ovarian cancer improves treatment completion and quality of life. METHODS: This pragmatic, cluster randomised controlled trial will be conducted at a minimum of 20 hospitals in the Netherlands. Hospitals are randomly assigned to geriatric screening care (in which a geriatric screening comprised of the G8 questionnaire and the Timed Up and Go test is performed), or care as usual (in which current usual care is continued). A total of 320 patients aged ≥ 70 years with primary, advanced-stage ovarian carcinoma will be included. Patients considered fit on geriatric screening will receive standard treatment; patients who are considered unfit will be referred to a geriatrician for analysis and treatment advice. The primary outcome is the percentage difference in completed standard and adapted therapies between the two study arms. Secondary outcomes include quality of life, cost-effectiveness and survival. DISCUSSION: This trial aims to gather evidence for the use of geriatric screening in treatment decision-making in elderly patients with advanced ovarian cancer. If proven feasible, beneficial and cost-effective, geriatric screening may be implemented in routine clinical practice. TRIAL REGISTRATION: Netherlands Trial Registry, ID: NL6745. Registered on 2 August 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. van Soolingen NJ, Smorenburg CH, Hamaker ME, et al. GERiatric Screening in the treatment of elderly patients with Ovarian Carcinoma (GERSOC): study protocol for a pragmatic, cluster randomised controlled trial. Trials. 2020. PMID: 32087750. doi:10.1186/s13063-020-4157-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。